NIH Biomarker Database, Oversight Panel Advocated By PhRMA
Executive Summary
The National Institutes of Health should devote seed money to the establishment and maintenance of a database to collect data from trials validating biomarkers and surrogate endpoints, the Pharmaceutical Research & Manufacturers of America urged at an April 15-16 NIH/FDA biomarkers conference in Bethesda, Md.